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Abstract 
Methotrexate (MTX) is a folate analogue antimetabolite widely used for the treatment 
of rheumatoid arthritis and cancer. A number of studies have shown that MTX 
delivered via nanoparticle carriers is more potent against cancer cells than free MTX, 
a phenomenon attributed to higher cellular uptake of the particles compared to the 
saturable folate receptor pathway. In this study, a cell-based global metabolic 
profiling approach was applied to study the effects of MTX in both free drug form 
and when encapsulated in -poly(lactide-co-glycolide) (PLGA) nanoparticles on a 
cancer cell line, A549, and also on human-like THP-1 macrophages. The results 
showed that MTX loaded nanoparticles had less impact on the macrophages than free 
MTX, and the effects on macrophages were limited to changes in nucleotide 
metabolism and suppression of the tricarboxylic acid cycle, whereas free MTX also 
led to a drop in glycolytic activity and impairment in redox homeostasis. In contrast, 
MTX loaded nanoparticles showed a greater impact on A549 cells than the free drug, 
which was in accord with studies in other cell lines in prior literature with MTX-
carrier nanoparticles. 
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1. Introduction 
The folate antagonist methotrexate (MTX), is used widely as an antiproliferative 
agent in cancer treatments and as an anti-inflammatory, particularly for rheumatoid 
arthritis. The mechanism of action is not completely understood for MTX yet, despite 
the drug first being introduced ~ 70 years ago as a cancer treatment.(Wojtuszkiewicz 
et al., 2015) MTX is known to inhibit the enzyme dihydrofolate reductase (DHFR) 
irreversibly,(Lin and Gerson, 2014) thus blocking the catalytic conversion of 
dihydrofolate to the active form tetrahydrofolate (THF). In turn, THF is essential for 
de novo purine, pyrimidine and neocluside thymidine synthesis which are required for 
DNA, RNA and thymidylates synthesis, MTX stops cell proliferation in the S phase, 
during which DNA replication takes place, by inhibiting nucleic acid and protein 
synthesis(Quéméneur et al., 2003). High-dose MTX has been used to treat 
malignancies (e.g., acute lymphoblastic leukaemia(Lonnerholm et al., 2009), non-
Hodgkin lymphoma(Canellos et al., 1981), osteosarcoma(van Dalen and de Camargo, 
2009), and colon cancer(Singh et al., 2006)), and to manage the symptoms of 
autoimmune diseases such as rheumatoid arthritis (RA)(Mikkelsen et al., 2011) at a 
lower dose. RA is a systemic chronic inflammatory joint disease, which is 
characterized by persistent synovitis, where macrophages are abundant and play a 
pivotal role.(Wang et al., 2012) Inhibition of DHFR is not enough to manage RA; 
therefore, MTX is assumed to have other mechanisms including inhibition of purine 
metabolism by inhibiting certain enzymes that are involved in that process. These 
include selective suppression of B cells, preventing T cell activation, downregulation 
of methyltransferase activity and inhibiting interleukin 1-beta binding to its receptor 
on the cell surface.(Böhm, 2004; Brody et al., 1993; Wessels et al., 2008) 
Malignant cells are highly proliferative, and DNA replication is essential for their 
survival, therefore these cells express high de novo nucleotide synthesis.(Tong et al., 
2009) MTX is capable of stopping the growth of cancer cells by inhibiting nucleobase 
synthesis, however, this effect of MTX can be counteracted by administration of folic 
acid. In contrast, although macrophages are not proliferative cells, the effects of MTX 
on macrophages are not modified by folic acid. These findings suggest that the 
mechanism of action of MTX is not limited to the inhibition of DNA replication and 
is cell-line dependent. 
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The mechanism by which MTX enters cells affects its activity, kinetics and fate. 
MTX is structurally similar to folic acid, it binds to folate receptors and is known to 
enter cells through active carrier-mediated transport (reduced folate carrier RFC) 
which makes it readily available in the cytoplasm. (Evans et al., 1986; Matherly and 
Hou, 2008) Once MTX is free in the cytosol, folylpolyglutamate synthase (FPGS) 
catalyses conversion of MTX to MTX-polyglutamate, rendering MTX no longer 
subject to the folate efflux pathway and prolonging retention inside the cells. In 
addition, polyglutamation increases the affinity of MTX for thymidylate synthetase 
(TS), phosphoribosyl aminoimidazole carboxamide formyltransferase and 
phosphoribosyl glycinamide formyltransferase (GART).(McBride et al., 2012; 
Wessels et al., 2008) The loading of MTX in nanoparticle carriers has been reported 
to enhance its activity in cell culture assays,(Gulfam et al., 2017; Maleki et al., 2017) 
which may be related to a change in the mechanism by which MTX enters cells when 
encapsulated. This is because many nanoparticles enter cells by passive endocytosis, 
which is not a saturable process, unlike the active transport of free MTX entry by 
reduced folate receptors.(Matherly and Hou, 2008)  
Metabolomics methods potentially allow all the end products of every cellular process 
to be measured, and any alterations in metabolite levels might act as signals which 
can describe the effects of certain stimuli on cells very comprehensively.(Nicholson 
and Lindon, 2008; Tiziani et al., 2011) We therefore chose LC-MS based metabolite 
profiling to investigate the effects of free MTX and MTX loaded NPs on selected 
cancer cells and macrophages. The resultant global metabolic profile data provide an 
explanation for the differences in cellular processing between fast proliferative cancer 
cells and non-proliferative human-like macrophages when challenged with MTX in 
free drug form and when encapsulated in polymeric nanoparticles. 
 
2. Materials and methods 
2.1. Materials 
RPMI 1640 medium, heat-inactivated FBS, penicillin, streptomycin, L-glutamine, 
Phorbol 12-myristate 13-acetate (PMA) and formaldehyde were purchased from 
Sigma-Aldrich. Ammonium carbonate was purchased from Fluka. Isopropanol and 
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acetonitrile were LC-MS grade and dichloromethane, methanol, diethyl ether and 
acetone were HPLC grade provided by Fisher Scientific. Fisher Scientific provided 
Trypan blue 0.4% and all HPLC/LC-MS grade solvents. 
 
THP-1 (human monocyte from acute monocytic leukaemia, ATCC® TIB-202™) and 
A549 (human adenocarcinoma alveolar basal epithelial, ATCC® CCL-185™) cells 
were cultured in RPMI and DMEM media respectively, supplemented with 10% FBS, 
2 mM L-glutamine, 100 μg/mL streptomycin and 100 U/mL penicillin, in a 
humidified atmosphere containing 5% CO2. The cells were used at passage number 
between 5-15. 
 
2.2. Nanoparticles preparation and charechterisztion. 
Nanoparticles were prepared using Fluorescein amine labelled PLGA to follow the 
cellular uptake. The fluorescently labelled PLGA was synthesised by using a 
fluorophore with an active nucleophilic moiety (Fluoresceinamine, isomer I) as 
initiator in a solvent-free ring opening polymerisation (ROP) reaction of lactide (LA) 
and glycolide (GA) monomers according to a previously described method  (Al-
Natour, 2019). Nanoparticles of these fluorescein amine labelled PLGA polymers 
were fabricated by a solvent precipitation from DMSO into aqueous suspension 
followed by dialysis in a procedure modified from a previous method.(Gulfam et al., 
2017). Accordingly, a sample (25 mg) of the PLGA polymer, dissolved in 10 mL 
DMSO, was introduced into Milli-Q water (10 mL) under vigorous stirring, using a 
syringe pump with a flow rate of 0.70 mL min−1. The solution was stirred for 10 
minutes at room temperature and NPs were purified by dialysis overnight against 1 L 
of Milli-Q water using a cellulose dialysis membrane (Spectrapor, cut-off 3500) to 
remove the DMSO. These NPs contained only fluorescent label and no drug and 
hence were termed ‘blank NPs’. Drug loaded NPs were prepared by a similar 
procedure, in which 2 mg MTX and 25 mg polymer were dissolved in 10 mL DMSO. 
Following precipitation in Milli-Q water and dialysis using the same procedure as for 
the blank NPs, the polymer NP suspensions were filtered through a membrane syringe 
filter (pore size: 0.22 μm) (Millex-LG, Millipore Co., USA) before further 
characterisation. Determination of drug contents and encapsulation efficiencies were 
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performed by dissolving a known amount (5 mg) of freeze dried MTX-loaded NPs in 
DMSO. The quantification of MTX was evaluated using UV-Vis spectrophotometry 
(monitoring at λmax = 304 nm). The amount of loaded drug was calculated using a 
standard curve of MTX in DMSO. Drug content (wt%) and encapsulation efficiency 
(wt%) were calculated according to the following equations:  
Drug content (wt%) = 
weight of MTX in NPs
weight of polymer used
 X 100 
Encapsulation efficiency (wt%) = 
weight of MTX in NPs
Total weight of MTX used
 X 100 
The in vitro drug release studies of MTX-loaded NPs were carried out in PBS, pH 
7.4, whereas 5 mg of freeze dried MTX-NPs were re-dispersed in 2 mL PBS (pH 7.4) 
and the solution was placed in a dialysis device (Slide-A-Lyzer™ mini dialysis 
device, 3.5 K MWCO, Thermo Scientific). The NP suspensions were dialysed against 
45 mL of release media (1 x PBS, pH 7.4) at 37 °C and samples (1 mL) were taken at 
appropriate time points and replaced with 1 mL fresh medium. The collected samples 
were freeze dried and dissolved in DMSO. The amount of MTX was calculated using 
UV-Vis spectrophotometry (λmax = 304 nm) via a standard calibration curve of MTX 
in DMSO, Table S1. 
 
2.3. Metabolic activity (AlamarBlue®) assay.  
In 250 µl of fully supplemented medium, THP-1 and A549 cells were seeded on 48-
well plates at densities of 250 x 103 cell/cm2 and 25 x 103 cell/cm2 respectively. After 
24 hours, the cells were washed with PBS and treated with Blank NPs, MTX loaded 
PLGA NPs, and free MTX for 24 hours. Thereafter, the cells were washed with PBS 
and the culture media were replaced with fresh fully supplemented media containing 
10% AlamarBlue® reagent for 4 hours. Finally, 100 μL were taken from each well 
and transferred to 96 black well plates and the fluorescence was measured on a 
TECAN plate reader at excitation/emission of 540/580 nm.  Six replicates from each 
condition were prepared and analysed.  The results are plotted as mean % viability vs 
control ± standard error of the mean (SEM).  
 
6 
 
2.4. Cellular uptake study 
For confocal microscopy, cells were seeded into 8-well chamber slides (obtained from 
Ibidi) at a seeding density of 3 x 105 cell/cm2 in 300 µl of fully supplemented 
medium. After 24 hours, the cells were treated with MTX loaded PLGA NPs for 3 
and 24 hours. Then, the cells were washed with PBS three times, fixed with 4% 
paraformaldehyde for 15 minutes, stained with Hoechst (20 µM in PBS for 10 
minutes) for the nucleus, stained with phalloidin Alexafluor 647 for cytoskeleton and 
covered with mounting medium. 
 
2.5. Metabolomic analysis  
2.5.1. MTX treatment and metabolite extraction 
THP-1 and A549 cells were seeded on T25 flasks (6 replicates for each condition) at a 
density of 2 x 105 cell/cm2 and 25 x 103 cell/cm2 fully supplemented RPMI 1640 
media and DMEM media respectively containing 50ng/ml PMA. After 24 hours, the 
cells were treated with free MTX, MTX loaded PLGA NPs and blank PLGA NPs for 
24 hours.  Then, after removing the medium, the cells were washed briefly once with 
pre-warmed PBS at 37 C. The cellular metabolism was rapidly-quenched and the 
metabolites were extracted simultaneously by adding 0.5 mL of methanol (−48 °C), 
and cell handling after quenching was performed on ice. The cells were then scraped 
and transferred to precooled fresh tubes at 4 C. Cell solution was vortexed 
vigorously for 1 h at 4 C and centrifuged at 17000 × g for 10 min at 4 °C. After the 
centrifugation, the supernatant was removed and dried under vacuum at room 
temperature. The metabolite extract was reconstituted using 70 µl of pre-cooled 
methanol (4 C). 10 µL aliquots were taken from each sample to make a pooled QC in 
order to assess instrument performance (Want et al., 2010a).  
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2.5.2. Liquid chromatography-mass spectrometry (LC-
MS) and data processing 
LC-MS analysis and data processing was performed according to a previously 
described procedure (Alazzo et al., 2019). Briefly, LC was performed on a ZIC-
pHILIC 5 μm, 4.6 × 150 mm column from Merck Sequant (Watford, UK), using an 
Accela LC system with a mobile phase consisting of A: 20 mM ammonium carbonate 
and B: 100% acetonitrile as previously described (Creek et al., 2011; Surrati et al., 
2016). Chromatographic separation was carried out using the following linear 
gradient: 20% A (0 min) to 95% A at 15 min to 20% A at 17 min and held to 24 min. 
The flow rate was 300 μl min−1 and the injection volume was 10 μl. Samples were 
maintained at 4 °C, and the column was maintained at 45 °C. 
MS was performed on an Orbitrap Exactive MS (Thermo Fisher Scientific, Hemel 
Hempstead, UK) with ESI running in positive and negative ionisation modes. Spectra 
were acquired in full MS scan in the range of m/z 70–1400. The capillary and probe 
temperatures were maintained at 275 and 150 °C, respectively. The instrument 
calibration was performed by modified Thermo calibration mixture masses with 
inclusion of C2H6NO2 (m/z 76.0393) for positive ion electrospray ionisation and 
C3H5O3 (m/z 89.0244) for negative ion electrospray ionisation in order to extend the 
calibration mass range to small metabolites. 
Data analysis and metabolite identification. 
Raw LC-MS data from the control group (untreated cells), the treatment groups (Free 
MTX and MTX loaded PLGA NPs, blank unloaded NPs), and reagent blanks were 
acquired using Xcalibur v2.1 software (Thermo Scientific, Hemel Hempstead UK), 
and processed with XCMS for untargeted peak-picking (Tautenhahn et al., 
2008). Peak matching and related peak annotation were performed using mzMatch 
(Scheltema et al., 2011) and noise filtering and putative metabolite identification were 
then carried out using IDEOM with the default parameters (Creek et al., 
2012). Metabolites that were matched with accurate masses and retention times of 
authentic standards were identified with Level 1 metabolite identification according to 
the metabolomics standards initiative (Sumner et al., 2007; Sumner et al., 2014), but 
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when standards were not available, metabolites were identified by employing 
predicted retention times considered as putative (Level 2 identification). Pooled QC 
samples were injected randomly in between every 5–6 samples to validate system 
suitability and stability (Want et al., 2010b). Multivariate data analysis was employed 
to assess changes in the cell metabolome between the control and each treatment 
group using orthogonal partial least squares discriminant analysis (OPLS-DA) using 
SIMCA-P v13.0.2 (Umetrics, Umea, Sweden)(Boccard and Rutledge, 2013). In 
addition to the multivariate analysis, univariate one-way ANOVA was carried out 
using Metaboanalyst 3.0.38 Mass ions with false discovery rate (FDR) less than 5% 
and variable importance in projection scores (VIP) greater than one were selected as 
significantly altered metabolites. The lists of significantly altered metabolites were 
imported to Metaboanalyst 3.0 to visualise the affected metabolic pathways(Kanehisa 
et al., 2014). 
 
 
3. Results and discussion  
Initial experiments demonstrated that the prepared NPs were well tolerated by both 
cells lines (Figure S1, S2), as evidenced by < 5 % changes in overall metabolic 
activity evaluated with Alamar Blue assays. A global LC-MS metabolic profiling 
approach was employed to study the effects of MTX and nanoparticles (NPs) with 
entrapped MTX (Table S1) on THP-1 and A549 cells respectively. Using Orbitrap 
coupled LC-MS, a total of 400 and 800 different metabolites were identified in THP-1 
and A549 cells respectively. These included amino acids, lipids, carbohydrates, 
nucleotides, cofactors and energy metabolism metabolites.  
Metabolic alterations were assessed primarily by OPLS-DA where a clear separation 
between the tested groups was observed, and the two cell lines showed different 
responses to free MTX, MTX loaded NPs and unloaded ‘blank’ PLGA NPs. The 
OPLS-DA plot for THP-1 cells (Figure 1 A) shows that the cells were sensitive to the 
treatment groups with NPs more than to free MTX, whereas MTX loaded NPs and 
blank PLGA NPs treated groups clustered close to each other. This implies that both 
MTX loaded PLGA NPs and the PLGA-only (i.e. ‘blank’)NPs affected the cells in a 
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similar manner, even though MTX is a potent drug and PLGA has been widely 
regarded as cytocompatible and is in existing clinical use in humans.  The metabolic 
changes observed in these cases can thus be interpreted as a consequence of the 
phagocytic nature of THP-1 cells. The presence of the NPs, which were of similar 
dimensions and charges (100-120 nm and between -27 and -47 mV, Table S1, ESI) to 
viral particles, might be expected to have activated strongly any phagocytosis 
processes and their accompanying metabolic changes(Saborano et al., 2017) in ways 
that may have been analogous to those in processing exogenous small molecule 
components.  Indeed, Saborano et al noted that macrophages exposed to a range of 
nanoparticles, including PLGA, expressed metabolic changes which inferred an 
inflammatory M1-type response. These were manifest in upregulation of glycolysis 
and the TCA cycle metabolites and thus were indicative of a phagocytic behavior in 
the presence of the NPs. However, it should be noted that the concentration of NPs in 
our study was 5-fold less than that used by Saborano et al, and thus while we 
therefore anticipated a phagocytic response to all the NPs in the study, the extent of 
the changes observed in macrophage metabolism in the presence of the blank NPs 
were in fact low compared to those induced by MTX-loaded NPs. 
As expected, the proliferative A549 cells were more sensitive to MTX, where MTX 
treated groups were not separable (see figure 1B), despite the fact that one group was 
treated with free MTX and the other was exposed to MTX loaded PLGA NPs. This 
indicated that MTX loaded NPs caused similar metabolic alterations in A549 cells to 
those caused by free MTX. 
Two-stage statistical analysis combining multivariate and univariate analysis was 
adopted to study further the key metabolites upon the different treatments to both cell 
lines. Metabolites responsible for the separation in the OPLS-DA models having VIP 
values greater than 1 were selected as changing metabolites. In addition, one way 
ANOVA was employed to enhance the statistical power of this study and the 
metabolites with FDR of <0.05 were further studied, Table S2, S3. Non-proliferative 
activated THP-1 macrophages were expected to tolerate MTX well because THP-1 
cells lose their proliferative ability once activated into macrophages, and MTX exerts 
its effect during the S phase in cellular proliferation.(Richter et al., 2016) 
Surprisingly, free MTX resulted in a decrease in the TCA cycle metabolites (2-
oxoglutarate, citrate and cis-aconitate) and in glycolytic activities 
(phosphoenolpyruvate, 3-phospho-D-glycerate and D-gluconic acid), as shown in 
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Table 1. Energy metabolism has a main role in macrophage polarisation, which 
results in either M1 macrophages that encourage inflammation, or in M2 
macrophages that suppress inflammation. It is well known that M1 polarisation 
depends on glycolysis and M2 polarisation relies on fatty acid oxidation 
(FAO).(Huang et al., 2014; Pearce and Pearce, 2013) The drop in glycolysis and the 
absence of any signs of FAO hyperactivity (no significant decrease in carnitine or 
increase in acylcarnitine) suggest that the macrophages were, however, not 
extensively polarised in these assays. In addition, downregulation of the TCA cycle 
results in depletion of ATP, which is essential for macrophage activation. These 
results suggest that impairing cellular energy production could be an important 
mechanism by which MTX controls the symptoms of RA by preventing macrophage 
polarisation to the inflammatory type M1. The pentose phosphate pathway is the main 
source of NADPH in the cell, and cellular redox homeostasis is maintained via 
NADPH which is used to recycle glutathione from its oxidised form. The results 
showed that administration of free MTX decreased the intracellular glutathione levels, 
this could be attributed to the drop in glucose metabolism, characterised by the 
depletion of gluconic acid. Unexpectedly, MTX loaded NPs did not affect the 
glycolytic activity, nor were the glutathione levels decreased. Another distinct 
fingerprint difference between the two types of macrophages (M1 and M2) is arginine 
metabolism, whereby the first type converts arginine to nitric oxide, which endows 
macrophages with cytostatic or cytotoxic activity against microorganisms, and the 
second type converts arginine to ornithine which is an anabolic promoter of cell 
proliferation. THP-1 cells treated with free MTX showed higher levels of ornithine, 
by a factor of 1.59: 1 compared to controls, potentially indicating an enhanced 
polarisation to an M2 anti-inflammatory macrophage phenotype, while for the MTX-
containing NPs the factor was 1.05:1. Metabolic profiling results also showed that 
free MTX had a greater impact on the metabolism of THP-1 cells in comparison to 
NPs loaded with MTX. In this case, MTX suppressed glycolytic activity, disturbed 
redox homeostasis, decreased TCA cycle activity and altered nucleotide metabolism 
(see Table 1), while MTX loaded NPs changed only TCA cycle activity and 
nucleotide metabolism. The variations in effects on the cell lines likely arose due to 
the differences between the concentrations of MTX in the cytoplasm. In the case of 
the drug alone, MTX would have been rapidly available following internalisation, 
whereas the NPs loaded MTX would have been trapped in phagosomes and 
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inaccessible during the initial stages in the cytoplasm, which is where all glycolytic 
activities take place. Over time, the phagosomes in macrophages fuse with lysosomes 
to produce phagolysosomes which are rich in hydrolytic enzymes and reactive oxygen 
species. MTX in free drug form is susceptible to oxidative degradation (Barisci et al., 
2015), whereas MTX entrapped in a nanoparticle core would have been less 
accessible to oxidants. 
In order to study this further, we evaluated the transport of MTX-loaded NPs in THP-
1 cells via super-resolution confocal microscopy (Figure 3). Within 3 hours of 
incubation, the MTX-containing nanoparticles were apparent within the cell interior, 
as demonstrated by distinct punctate regions of the green fluorescent NPs in the 
cytosol. It is noteworthy that no diffuse staining of the cytoplasm was observed in 
these images, indicating that the polymer NPs were retained by intracellular 
compartments over this time period. In turn, this could also indicate that export of 
MTX by the normal folate-carrier type recycling pathways did not take place, as these 
processes have been reported to take place with periods much less than 1 hr in vitro, 
albeit in a panel of cancer cell lines.(Paulos et al., 2006) Nevertheless, given that both 
internalization and export kinetics of folate-receptor pathways are very rapid, the 
retention of the MTX-containing NPs was indicative of a different transport process 
for these materials compared to MTX, and thus a likely different exposure of cellular 
components to MTX delivered via the PLGA carrier than as a free drug. These results 
also support other papers which have demonstrated that nanoparticle- or polymer 
surfactant-mediated transport is more effective for delivering anti-cancer agents to 
target cells compared to that of the free drug through modification of internalization 
and export pathways.(Batrakova et al., 2010) 
 
Further effects on cell processes were apparent in terms of nucleotide metabolism, 
which was altered both by free MTX and MTX loaded NPs. Thymidine synthesis, 
which starts by reduction of uridine to deoxyuridine, followed by phosphorylation to 
produce dUMP and methylation by thymidylate synthase to produce thymidine 
monophosphate was reduced. This occurred via suppression of thymidylate synthase 
by MTX, and as a result, the levels of deoxyuridine and dUMP were higher in MTX 
and MTX loaded NPs treated groups in comparison to the control groups. Secondly, 
de novo purine synthesis was also suppressed by both treatments, in particular, the 
third step where the enzyme phosphoribosylglycinamide formyltransferase (GART) 
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catalyses the formation of 5'-phosphoribosyl-N-formylglycinamide (FGAR) from 5'-
phosphoribosyl-glycinamide (GAR) resulting in accumulation of GAR, (see Figure 
2). 
As a comparator, the A549 lung cancer cells showed early signs of apoptosis upon 
treatment with free MTX and MTX loaded NPs. The levels of choline, 
phosphocholine, and glutathione were lower compared to the untreated groups. 
Similar changes have been reported in apoptotic cells,(Halama et al., 2013a; Halama 
et al., 2013b; Rainaldi et al., 2008) accompanied by increased fatty acid oxidation 
(FAO). The levels of several acylcarnitines i.e. hexadecanoyl-carnitine, O-hexanoyl-
carnitine, palmitoyl-carnitine and 2-hydroxylauroylcarnitine, were higher in the MTX 
treated groups (see Table 1). A shift toward FAO can occur during energy crisis, 
when cells cannot produce enough ATP from glucose metabolism, or to survive 
oxidative stress.(Carracedo et al., 2013) Cancer cells generally prefer glucose 
metabolism to harness energy rapidly, in a process known as the Warburg 
Effect,(Vander Heiden et al., 2009) but also recycle glutathione from its oxidised 
form in order to retain cellular redox homeostasis. Free MTX and MTX loaded NPs 
treated groups showed a decrease in glutathione, suggestive of oxidative stress 
mechanisms. Indeed MTX has previously been reported to exert cytotoxic effects by 
inducing oxidative stress(Akacha et al., 2018) and this could explain the upregulation 
of FAO observed. In contrast to the effects in THP-1 cells, treating the cancer cells 
with MTX-loaded NPs induced more metabolic changes than when free MTX was 
administered. A549 cells treated with MTX-loaded NPs showed depletion in 
hypoxanthine, adenine, adenosine and AMP, which are four consecutive metabolites 
in the purine metabolism pathway. In addition, an increased GAR level indicated 
suppression in purine metabolism. On the other hand, free MTX resulted in depletion 
of AMP only, and an increase in GAR. The degree of purine synthesis inhibition 
could thus be considered as a measure for the potency of MTX inside the cells. The 
increased activity of the MTX-loaded NPs could, as noted earlier, be attributed to the 
fact that the NPs entered the cells via passive endocytosis, allowing higher uptake 
compared to the RFC-mediated transport of MTX alone.(Gulfam et al., 2017) The 
saturation of folate-receptor pathways via MTX is well-known, whereas the 
internalisation routes for nanoparticles are highly cell-, and polymer-type, 
dependent.(Zhang et al., 2015) In our case, the effects of MTX, and MTX-loaded NPs 
were different in the two cell lines, and thus were indicative of a modification of the 
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cellular activities of MTX as a consequence of the delivery, rather than of the drug 
itself. Nevertheless, the fact that LC-MS metabolomics data were able to establish the 
differences in MTX activity are promising, and suggest that such an approach might 
be used to probe further the individual pathways along putative internalization routes. 
Experiments to evaluate in greater detail this hypothesis are under way and will be 
reported in a future manuscript. 
 
4. Conclusion 
In this study, THP-1 derived macrophages and A549 lung carcinoma cells were 
exposed to subtoxic concentrations of free MTX and MTX loaded NPs, and global 
metabolic profiling was performed. The results showed that free MTX had higher 
impacts on the metabolome than MTX-loaded NPs in THP-1 derived macrophages. In 
these cells, MTX induced oxidative stress, a drop in glycolytic activity, reduction in 
the TCA cycle, and inhibition of nucleotide metabolism. In contrast, the effects of 
MTX-loaded NPs were limited to alteration of nucleotide metabolism and inhibition 
of TCA cycle. In comparison, A549 cancer cells were more susceptible to MTX-
loaded NPs than to the free drug, in terms of purine synthesis suppression, which we 
suggest was linked to the different entry mechanisms for nanoparticles compared to 
free MTX, and lack of efflux pumps for the NPs. We believe the presented work 
shows that metabolomics is a valuable analytical technique that can be used to 
understand mechanisms of action of drugs and formulations in various clinically 
important cell lines. 
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Figures and Tables 
 
Figure 1 (A) OPLS-DA scores plots of THP-1 cells samples (R2X=0.616, R2Y=0.99 Q2=0.68, 
CV-ANOVA p-value 0.0083, n=6). B) A549 cells samples (R2X=0.84, R2Y=0.98, Q2=0.82, 
CV-ANOVA p-value 1.7e-6, n=6) after 24 hour treatment with free MTX, MTX loaded PLGA 
NPs and blank PLGA NPs. (the control group without any treatment). 
  
A 
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Figure 2 Overview of the affected pathways in the THP-1 cells after treatment with the free 
MTX and MTX loaded NPs. Red arrow = increased, blue arrow = decreased, Methotrexate 
enters the cell mainly via reduced folate receptor (RCF). Folylpolyglutamyl synthetase 
(FPGS) catalyses the polyglutamation of MTX to produce MTX polyglutamates (MTX-PGs). 
MTX-PGs are better retained intracellularly than MTX because they are not susceptible to the 
ATP-binding cassette (ABC) that is responsible for MTX efflux. MTX-PGs have higher affinity 
than MTX to thymidylate synthetase (TS) and phosphoribosylglycinamide formyltransferase 
(GART). Deoxyuridine-5-monophosphate (dUMP), deoxythymidine monophosphate (dTMP), 
5'-phosphoribosyl-glycinamide (GAR), 5'-phosphoribosyl-N-formylglycinamide (FGAR) and 
nitric oxide (NO). 
Pathway analysis was performed using Metaboanalyst 3.0 software following LC-MS assays 
of cell (THP-1 and A549) extracts following incubation with MTX and MTX-loaded NPs for 
24hr. 
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Figure 3: Super-resolution microscopy image of methotrexate loaded PLGA nanoparticles 
(green) (92 μg/mL, 3 hrs) in THP-1 derived macrophages. Cells were fixed and stained for 
cytoskeleton (Alexafluor 647, magenta) and nucleus (Hoechst nucleus, blue). Scale bar = 20 
µm. 
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Table 1: Biologically relevant metabolites which changed significantly in THP-1 and A549 
cells after treatment with free MTX and MTX loaded NPs, IDC: metabolite identification level 
according to metabolomics standards initiative L1 – Level 1, L2 – Level 2.  Colours represent 
changes in metabolite levels with blue indicating a decrease and red denoting an increase. 
 
 THP-1 cells 
Mass RT FORMULA Putative metabolite IDC 
MTX 
NPS 
Free 
MTX 
 Redox homeostasis 
307.0838 9.80 C10H17N3O6S Glutathione L1 1.01 0.65 
612.1523 11.00 C20H32N6O12S2 Glutathione disulfide L1 0.80 0.97 
132.0898 16.19 C5H12N2O2 Ornithine L1 1.46 1.91 
 Energy metabolism 
146.0215 10.32 C5H6O5 2-Oxoglutarate L2 0.71 0.59 
192.0270 11.72 C6H8O7 Citrate L2 0.70 0.43 
174.0164 11.29 C6H6O6 cis-Aconitate L2 0.71 0.39 
167.9823 11.42 C3H5O6P Phosphoenolpyruvate L1 1.02 0.43 
 Nucleotide Metabolism 
286.0567 10.72 C7H15N2O8P GAR L2 17.12 8.20 
308.0411 9.41 C9H13N2O8P dUMP L1 1017 705 
228.0747 7.84 C9H12N2O5 Deoxyuridine L2 7.88 9.20 
       
 A549 Cells 
Mass RT FORMULA Putative metabolite  
MTX 
NPS 
Free 
MTX 
 Redox homeostasis and apoptotic markers 
307.0837 9.77 C10H17N3O6S Glutathione L1 0.72 0.74 
306.0759 10.83 C20H32N6O12S2 Glutathione disulfide L1 0.93 0.84 
183.0661 10.15 C5H14NO4P Choline phosphate L1 0.64 0.84 
103.0997 10.43 C5H13NO Choline L2 0.47 0.59 
 Energy metabolism 
260.0297 10.46 C6H13O9P Fructose 6-phosphate L1 0.66 0.64 
359.2670 5.51 C19H37NO5 2-Hydroxylauroylcarnitine L2 2.29 2.03 
259.1784 5.72 C13H25NO4 Hexanoylcarnitine L2 2.09 2.17 
397.3190 5.19 C23H43NO4 Hexadecenoylcarnitine L2 1.96 2.32 
425.3503 5.08 C25H47NO4 Elaidiccarnitine L2 1.69 1.82 
387.2983 5.49 C21H41NO5 2-Hydroxymyristoylcarnitine L2 1.66 1.87 
371.3034 5.28 C21H41NO4 Tetradecanoylcarnitine L2 1.60 1.79 
 Nucleotide Metabolism 
136.0384 8.89 C5H4N4O Hypoxanthine L1 0.81 1.42 
267.0967 8.22 C10H13N5O4 Adenosine L1 0.74 1.74 
135.0545 8.64 C5H5N5 Adenine L1 0.79 1.10 
347.0630 9.46 C10H14N5O7P AMP L1 0.64 0.65 
286.0565 10.56 C7H15N2O8P GAR L2 11.46 9.78 
Table S1: Size and zeta potential of the blank and MTX loaded NPs. 
Type of NPs Mean Diameter (nm) Zeta potential (mv) 
Blank NPs 120 ± 1.4 -46.7 ± 2.5 
MTX NPs 129 ± 2.0 -27.1 ± 3.3 
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Figure S1: Viability of activated THP-1 macrophages following exposure to free 
and polymer encapculated methotrexate for 24 hrs. 
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Figure S2: Viability of A549 cells following exposure to free and polymer 
encapculated methotrexate for 24 hrs. 
 
Table S1: The metabolites that were changed significantly in THP-1 derived macrophages after the treatment with free and polymer-
encapsulated methotrexate, IDC: metabolite identification level according to the metabolomics standards initiative L1 – Level 1, L2 – Level 
2. Colours in the table represent changes in metabolite levels with blue indicating a decrease and red denoting an increase. 
Mass Polarity 
Mass 
error 
(ppm) 
RT FORMULA Putative metabolite IDC Map Control MTX 
MTX 
NPS 
84.0211 + -0.22 8.96 C4H4O2 3-Butynoate L2 Carbohydrate Metabolism 1.00 0.42 0.42 
109.0198 + 0.467 11.13 C2H7NO2S Hypotaurine L2 Amino Acid Metabolism 1.00 0.67 0.86 
113.0478 - 0.802 10.16 C5H7NO2 Pyrroline-5-carboxylate L2 Amino Acid Metabolism 1.00 0.87 0.55 
117.0538 + -0.56 11.71 C3H7N3O2 Guanidinoacetate L1 Amino Acid Metabolism 1.00 0.95 0.98 
117.079 + -0.32 9.25 C5H11NO2 Betaine L1 Amino Acid Metabolism 1.00 0.76 0.84 
118.0267 - 0.806 10.12 C4H6O4 Succinate L1 Carbohydrate Metabolism 1.00 1.27 1.43 
120.0423 - 0.303 10.95 C4H8O4 Erythrulose L2 Carbohydrate Metabolism 1.00 1.07 0.93 
125.0589 + -0.37 11.71 C5H7N3O 5-Methylcytosine L2 Nucleotide Metabolism 1.00 1.05 1.13 
127.0634 + 0.241 10.21 C6H9NO2 2,3,4,5-Tetrahydropyridine-2-carboxylate L2 Amino Acid Metabolism 1.00 0.67 0.81 
129.0427 - 0.731 6.35 C5H7NO3 1-Pyrroline-4-hydroxy-2-carboxylate L2 Amino Acid Metabolism 1.00 0.99 0.65 
130.0631 - 0.884 4.79 C6H10O3 3-Methyl-2-oxopentanoic acid L2 Amino Acid Metabolism 1.00 0.74 0.68 
131.0583 + 0.655 10.89 C5H9NO3 Glutamate 5-semialdehyde L2 Amino Acid Metabolism 1.00 0.87 0.83 
131.0946 + -0.44 9.31 C6H13NO2 Leucine L1 Amino Acid Metabolism 1.00 0.77 0.81 
132.0534 + -0.75 8.85 C4H8N2O3 N-Carbamoylsarcosine L2 Amino Acid Metabolism 1.00 1.58 1.26 
132.0899 + -0.26 16.12 C5H12N2O2 Ornithine L1 Amino Acid Metabolism 1.00 1.59 1.05 
136.0384 + -0.93 8.98 C5H4N4O Hypoxanthine L1 Nucleotide Metabolism 1.00 2.65 0.62 
140.0585 + -0.61 7.39 C6H8N2O2 Methylimidazoleacetic acid L2 Amino Acid Metabolism 1.00 0.87 0.76 
141.0191 - 0.373 10.88 C2H8NO4P Ethanolamine phosphate L1 Amino Acid Metabolism 1.00 0.95 1.25 
145.0851 + -0.45 11.32 C5H11N3O2 4-Guanidinobutanoate L2 Amino Acid Metabolism 1.00 0.81 1.00 
146.0691 + -0.67 10.94 C5H10N2O3 Glutamine L1 Amino Acid Metabolism 1.00 0.95 0.94 
148.0372 - 0.589 10.1 C5H8O5 2-Hydroxyglutarate L1 Amino Acid Metabolism 1.00 0.61 0.82 
149.051 + -0.8 9.43 C5H11NO2S Methionine L1 Amino Acid Metabolism 1.00 0.82 0.86 
150.0527 - -0.28 11.04 C5H10O5 Xylulose L2 Carbohydrate Metabolism 1.00 0.98 0.94 
155.0695 + -0.23 11.18 C6H9N3O2 Histidine L2 Amino Acid Metabolism 1.00 0.84 0.85 
158.0439 - -0.12 10.86 C4H6N4O3 Allantoin L1 Nucleotide Metabolism 1.00 0.87 0.85 
159.126 + 0.076 5.65 C8H17NO2 FA amino(8:0) L2 Lipids: Fatty Acyls 1.00 1.54 1.29 
161.0687 + -0.65 9.04 C6H11NO4 O-Acetyl-L-homoserine L2 Amino Acid Metabolism 1.00 0.46 0.73 
163.0481 - 0.456 8.67 C5H9NO5 L-erythro-4-Hydroxyglutamate L2 Amino Acid Metabolism 0.00 0.00 11.79 
165.079 + -0.29 8.64 C9H11NO2 Phenylalanine L2 Amino Acid Metabolism 1.00 0.83 0.78 
169.0044 - 0.063 10.91 C3H7NO5S L-Cysteate L1 Amino Acid Metabolism 1.00 0.73 0.82 
169.9981 - 0.934 11.03 C3H7O6P Glyceraldehyde 3-phosphate L2 Carbohydrate Metabolism 1.00 1.25 0.92 
174.0791 + -1.34 7.25 C10H10N2O Indole-3-acetamide L2 Amino Acid Metabolism 1.00 0.32 0.52 
175.0633 + -0.47 4.49 C10H9NO2 5-Hydroxyindoleacetaldehyde L2 Amino Acid Metabolism 1.00 0.90 0.58 
175.0957 + -0.53 11.4 C6H13N3O3 Citrulline L1 Amino Acid Metabolism 1.00 0.88 0.94 
179.0582 - 0.535 5.42 C9H9NO3 Hippurate L1 Amino Acid Metabolism 1.00 1.04 0.72 
181.074 + 0.473 10.21 C9H11NO3 Tyrosine L1 Amino Acid Metabolism 1.00 0.88 0.82 
182.0791 - 0.852 10.47 C6H14O6 Sorbitol L2 Carbohydrate Metabolism 1.00 0.97 1.00 
188.1273 + -0.33 18.52 C7H16N4O2 Homoarginine L2 Amino Acid Metabolism 1.00 1.19 0.93 
189.1 - 0.228 5.43 C8H15NO4 2 -(Butylamido)-4-hydroxybutanoic acid L2 - 1.00 1.11 81.74 
203.1157 + -0.56 8.95 C9H17NO4 O-Acetylcarnitine L1 Amino Acid Metabolism 1.00 0.40 0.44 
204.1475 + 0.049 14.22 C9H20N2O3 3-Hydroxy-N6,N6,N6-trimethyl-L-lysine L2 Amino Acid Metabolism 1.00 0.82 0.78 
208.0848 + -0.5 9.22 C10H12N2O3 Kynurenine L1 Amino Acid Metabolism 1.00 0.86 0.81 
215.0559 - 0.649 11.08 C5H14NO6P sn-glycero-3-Phosphoethanolamine L2 Lipid Metabolism 1.00 0.70 0.81 
216.0401 - 1.701 12.08 C5H13O7P 2-C-Methyl-D-erythritol 4-phosphate L2 Lipid Metabolism 1.00 0.74 0.92 
226.1066 + -0.42 11.26 C9H14N4O3 Carnosine L2 Amino Acid Metabolism 1.00 0.71 0.76 
231.1471 + -0.47 7.92 C11H21NO4 O-Butanoylcarnitine L1 Lipids: Fatty Acyls 1.00 0.55 0.69 
257.103 + 0.06 10.51 C8H20NO6P sn-glycero-3-Phosphocholine L1 Lipid Metabolism 1.00 0.87 0.79 
259.1784 + -0.56 7.29 C13H25NO4 O-hexanoyl-R-carnitine L2 Lipids: Fatty Acyls 1.00 0.47 0.45 
264.1045 + -0.4 18.46 C12H16N4OS Thiamin L2 Metabolism of Cofactors and Vitamins 1.00 0.92 0.79 
278.1519 - 0.989 4.26 C16H22O4 Alpha-CEHC L2 - 1.00 0.77 0.86 
299.2824 + -0.67 6.21 C18H37NO2 FA (16:2) L2 Lipids: Fatty Acyls 1.00 0.94 1.19 
324.0361 - 1.312 10.05 C9H13N2O9P UMP L1 Nucleotide Metabolism 1.00 1.07 1.11 
369.2879 + -0.46 5.39 C21H39NO4 cis-5-Tetradecenoylcarnitine L2 - 1.00 0.48 0.49 
371.3036 + -0.48 5.36 C21H41NO4 Tetradecanoylcarnitine L2 - 1.00 0.40 0.43 
384.1217 + -0.2 10.15 C14H20N6O5S Adenosyl-L-homocysteine L2 Amino Acid Metabolism 1.00 1.16 1.29 
425.3505 + -0.37 5.14 C25H47NO4 Elaidiccarnitine L2 - 1.00 0.49 0.49 
427.3662 + -0.32 5.11 C25H49NO4 Stearoylcarnitine L2 - 1.00 0.51 0.61 
446.0604 - 0.915 10.9 C11H20N4O11P2 CDP-ethanolamine L2 Lipid Metabolism 1.00 1.00 1.41 
472.1126 + 0.182 9.85 C14H26N4O10P2 CMP-N-trimethyl-2-aminoethylphosphonate L2 Lipid Metabolism 1.00 2.50 2.19 
479.3011 + -0.39 5.04 C23H46NO7P PE (18:1) L2 Lipids: Glycerophospholipids 1.00 1.30 1.11 
488.1077 + 0.513 10.32 C14H26N4O11P2 CDP-choline L2 Lipid Metabolism 1.00 1.88 1.70 
523.291 - 1.192 4.39 C24H46NO9P PS (18:1) L2 Lipids: Glycerophospholipids 1.00 1.41 1.06 
593.575 - 1.884 4.57 C38H75NO3 SP (20:0) L2 Lipids: Sphingolipids 1.00 1.87 1.46 
619.59 + -0.32 4.53 C40H77NO3 Cer(d-40:2) L2 Lipids: Sphingolipids 1.00 1.26 1.04 
673.5045 + 0.019 4.56 C37H72NO7P PE(P-32:1) L2 Lipids: Glycerophospholipids 1.00 0.77 0.98 
729.5309 + 0.136 4.73 C40H76NO8P PC(32:2) L2 Lipids: Glycerophospholipids 1.00 0.78 1.00 
733.5628 + 0.978 4.72 C40H80NO8P PC(32:0) L2 Lipids: Glycerophospholipids 1.00 0.93 1.19 
759.5774 + -0.58 4.7 C42H82NO8P PC(34:1) L2 Lipids: Glycerophospholipids 1.00 0.85 1.03 
776.5571 - 1.592 4.22 C42H81O10P PG(36:1) L2 Lipids: Glycerophospholipids 1.00 0.70 1.18 
787.609 + -0.23 4.7 C44H86NO8P PC(36:1) L2 Lipids: Glycerophospholipids 1.00 0.85 0.99 
820.5258 - 1.093 4.07 C46H77O10P PG(40:7) L2 Lipids: Glycerophospholipids 1.00 0.78 0.83 
879.5838 + -0.06 4.17 C45H86NO13P PI (36:0) L2 Lipids: Glycerophospholipids 1.00 1.02 0.87 
883.535 + -1.65 4.07 C50H78NO10P PS(44:10) L2 Lipids: Glycerophospholipids 1.00 0.90 1.00 
 
 
Table S1: The metabolites that were changed significantly in A549 cells after the treatment with free and polymer-encapsulated 
methotrexate, IDC: metabolite identification level according to the metabolomics standards initiative L1 – Level 1, L2 – Level 2. Colours in 
the table represent changes in metabolite levels with blue indicating a decrease and red denoting an increase. 
Mass Polarity 
Mass error 
(ppm) 
RT FORMULA Putative metabolite IDC Map Control MTX MTX NPs 
78.0139 + -1.518 7.25 C2H6OS Mercaptoethanol L2 Medium Component 1 4.44 3.78 
84.0211 + -1.519 10.36 C4H4O2 3-Butynoate L2 Carbohydrate Metabolism 1 1.45 1.44 
89.0477 + -1.619 11.19 C3H7NO2 Alanine L1 Amino Acid Metabolism 1 1.06 1.03 
103.0633 + -2.095 11.18 C4H9NO2 4-Aminobutanoate L2 Amino Acid Metabolism 1 0.68 0.62 
105.0426 + -1.48 6.03 C3H7NO3 2-Amino-3-hydroxypropanoic acid L2 Lipids: Fatty Acyls 1 1.16 1.03 
105.079 + -1.534 15.28 C4H11NO2 Diethanolamine L2 Lipid Metabolism 1 0.27 0.19 
109.0198 + -1.41 11.04 C2H7NO2S Hypotaurine L2 Amino Acid Metabolism 1 0.9 0.97 
112.1252 + -1.744 4.5 C8H16 3-methyl-1-heptene L2 Lipids: Fatty Acyls 1 1.29 1.08 
113.0477 + -1.325 7.26 C5H7NO2 (S)-1-Pyrroline-5-carboxylate L2 Amino Acid Metabolism 1 1.48 1.57 
113.0589 + -1.32 8.59 C4H7N3O Creatinine L2 Amino Acid Metabolism 1 1.14 1.11 
117.0538 + -1.97 11.64 C3H7N3O2 Guanidinoacetate L1 Amino Acid Metabolism 1 1.13 1.03 
117.079 + -1.62 9.12 C5H11NO2 Betaine L1 Amino Acid Metabolism 1 1.39 1.35 
122.048 + -1.42 7.32 C6H6N2O Nicotinamide L1 
Metabolism of Cofactors 
and Vitamins 
1 1.28 1.09 
127.0382 + -1.162 9.12 C4H5N3O2 5-Amino-4-imidazole carboxylate L2 Nucleotide Metabolism 0 94.12 103.21 
129.0426 + -1.274 5.9 C5H7NO3 1-Pyrroline-3-hydroxy-5-carboxylate L2 Amino Acid Metabolism 1 1.34 0.98 
129.0426 + -1.326 7.46 C5H7NO3 1-Pyrroline-4-hydroxy-2-carboxylate L2 Amino Acid Metabolism 1 1.14 0.97 
129.079 + -1.539 7.22 C6H11NO2 N4-Acetylaminobutanal L2 Amino Acid Metabolism 1 0.79 0.77 
131.0583 + -1.449 10.75 C5H9NO3 L-Glutamate 5-semialdehyde L2 Amino Acid Metabolism 1 0.71 0.69 
131.0583 + -1.424 5.57 C5H9NO3 N-Acetyl-beta-alanine L2 Amino Acid Metabolism 1 1.12 1.23 
131.0695 + -1.542 10.94 C4H9N3O2 Creatine L1 Amino Acid Metabolism 1 1.01 0.9 
132.0899 + -1.856 16.19 C5H12N2O2 L-Ornithine L1 Amino Acid Metabolism 1 1.46 1.28 
136.0636 + -1.929 20.58 C7H8N2O 1-Methylnicotinamide L2 
Metabolism of Cofactors 
and Vitamins 
1 0.88 1.02 
140.0586 + -1.851 5.68 C6H8N2O2 Methylimidazoleacetic acid L2 Amino Acid Metabolism 1 0.41 0.36 
144.0422 + -1.786 10.37 C6H8O4 2,3-Dimethylmaleate L2 
Metabolism of Cofactors 
and Vitamins 
1 1.35 1.46 
145.0739 + -1.792 5.64 C6H11NO3 4-Acetamidobutanoate L2 Amino Acid Metabolism 1 0.44 0.37 
145.0851 + -2.031 11.25 C5H11N3O2 4-Guanidinobutanoate L2 Amino Acid Metabolism 1 1.02 0.92 
145.1103 + -1.784 10 C7H15NO2 4-Trimethylammoniobutanoate L1 Amino Acid Metabolism 1 1.25 1.2 
146.0691 + -2.163 10.85 C5H10N2O3 Glutamine L1 Amino Acid Metabolism 1 2.06 2.22 
146.1054 + -2.359 17.25 C6H14N2O2 Lysine L2 Amino Acid Metabolism 1 1.39 1.25 
147.0531 + -1.988 9.99 C5H9NO4 Glutamate L2 Amino Acid Metabolism 1 1.77 1.54 
161.0688 + -1.865 8.95 C6H11NO4 O-Acetyl-L-homoserine L2 Amino Acid Metabolism 1 0.27 0.21 
169.0504 + -2.021 9.73 C4H12NO4P Phosphodimethylethanolamine L2 Lipid Metabolism 1 0.79 0.71 
169.0739 + -1.696 7.48 C8H11NO3 Pyridoxine L2 
Metabolism of Cofactors 
and Vitamins 
1 1.58 1.43 
174.1117 + -1.571 18.34 C6H14N4O2 Arginine L1 Amino Acid Metabolism 1 1.41 1.21 
175.0634 + -1.673 4.37 C10H9NO2 5-Hydroxyindoleacetaldehyde L2 Amino Acid Metabolism 1 1.74 1.66 
179.0795 + -1.268 10.39 C6H13NO5 Glucosamine L2 Carbohydrate Metabolism 1 1.46 1.49 
181.074 + -1.151 10.19 C9H11NO3 Tyrosine L1 Amino Acid Metabolism 1 1.38 1.24 
182.0788 - -2.875 10.44 C6H14O6 Sorbitol L2 Carbohydrate Metabolism 1 1.16 1.22 
183.0661 + -1.574 10.15 C5H14NO4P Choline phosphate L1 Lipid Metabolism 1 0.84 0.64 
188.1525 + -1.732 15.8 C9H20N2O2 N6,N6,N6-Trimethyl-L-lysine L2 Amino Acid Metabolism 1 1.02 0.87 
193.0741 + -0.91 5.04 C10H11NO3 Phenylacetylglycine L2 Amino Acid Metabolism 1 1.36 1.31 
203.1157 + -1.933 8.85 C9H17NO4 O-Acetylcarnitine L1 Amino Acid Metabolism 1 0.68 0.72 
204.0899 + -1.895 9.68 C11H12N2O2 Tryptophan L1 Amino Acid Metabolism 1 0.86 0.78 
211.0357 + -2.163 10 C4H10N3O5P Phosphocreatine L2 Amino Acid Metabolism 1 0.89 0.68 
217.1313 + -2.242 8.28 C10H19NO4 O-Propanoylcarnitine L2 Lipids: Fatty Acyls 1 0.72 0.6 
219.1107 + -1.906 7.22 C9H17NO5 Pantothenate L1 Amino Acid Metabolism 1 1.4 1.29 
257.1028 + -2.086 10.43 C8H20NO6P sn-glycero-3-Phosphocholine L1 Lipid Metabolism 1 0.66 0.5 
262.0888 + -2.115 7.43 C12H14N4OS Thiamine aldehyde L2 
Metabolism of Cofactors 
and Vitamins 
1 2.17 2.11 
264.1044 + -2.209 18.82 C12H16N4OS Thiamin L2 
Metabolism of Cofactors 
and Vitamins 
1 0.86 0.98 
279.2562 + -1.95 4.86 C18H33NO Linoleamide L2 Lipids: Fatty Acyls 1 1.33 1.21 
297.0895 + -2.202 7.24 C11H15N5O3S 5'-Methylthioadenosine L1 Amino Acid Metabolism 1 1.24 1.14 
304.2401 - -2.723 4.12 C20H32O2 FA (20:4) L2 Lipids: Fatty Acyls 1 2.26 1.07 
306.2557 - -2.8 4.12 C20H34O2 Icosatrienoic acid L2 Lipids: Fatty Acyls 1 1.42 0.72 
307.0837 + -2.296 9.77 C10H17N3O6S Glutathione L2 Amino Acid Metabolism 1 0.74 0.72 
371.3034 + -2.105 5.28 C21H41NO4 Tetradecanoylcarnitine L2 - 1 1.79 1.6 
397.319 + -1.963 5.19 C23H43NO4 Hexadec-2-enoylcarnitine L2 - 1 2.32 1.96 
399.3347 + -2.01 5.15 C23H45NO4 O-Palmitoyl-R-carnitine L2 Lipids: Fatty Acyls 1 2.14 1.84 
425.3503 + -1.936 5.08 C25H47NO4 Elaidiccarnitine L2 - 1 1.82 1.69 
437.2903 - -2.645 4.99 C21H44NO6P PE (16:1) L2 Lipids: Glycerophospholipids 1 1.57 1.24 
467.301 + -1.636 5.31 C22H46NO7P PC (14:0) L2 Lipids: Glycerophospholipids 1 2.07 1.57 
479.301 + -1.707 4.97 C23H46NO7P PE (18:1) L2 Lipids: Glycerophospholipids 1 1.7 1.32 
481.3531 + -1.439 5.23 C24H52NO6P PC (16:2) L2 Lipids: Glycerophospholipids 1 1.55 1.1 
493.3165 + -1.818 5.23 C24H48NO7P PC (16:1) L2 Lipids: Glycerophospholipids 1 2.13 1.51 
495.3322 + -1.689 5.18 C24H50NO7P PC (16:0) L2 Lipids: Glycerophospholipids 1 2.05 1.48 
507.3687 + -1.439 5.13 C26H54NO6P PC (18:1) L2 Lipids: Glycerophospholipids 1 1.55 1.09 
519.3328 + -0.408 5.15 C26H50NO7P PC (18:2) L2 Lipids: Glycerophospholipids 1 2.95 2.17 
537.5117 - -2.498 4.5 C34H67NO3 SP (16:0) L2 Lipids: Sphingolipids 1 1.47 1.54 
721.5042 + -1.725 4.43 C41H72NO7P PE(P-36:4) L2 Lipids: Glycerophospholipids 1 1.3 1.29 
723.5199 + -1.616 4.44 C41H74NO7P PE(P-36:4) L2 Lipids: Glycerophospholipids 1 1.36 1.29 
743.5464 + -1.349 4.51 C41H78NO8P PE(36:2) L2 Lipids: Glycerophospholipids 1 1.46 1.26 
747.5199 + -1.714 4.42 C43H74NO7P PE (38:7) L2 Lipids: Glycerophospholipids 1 1.3 1.25 
765.5308 + -1.376 4.43 C43H76NO8P PE(38:5) L2 Lipids: Glycerophospholipids 1 1.32 1.36 
767.5464 + -1.525 4.44 C43H78NO8P PE(38:4) L2 Lipids: Glycerophospholipids 1 1.33 1.34 
771.6139 + -1.712 4.66 C44H86NO7P PC (36:1) L2 Lipids: Glycerophospholipids 1 1.24 0.98 
787.5359 - -2.214 4.09 C42H78NO10P PS(36:2) L2 Lipids: Glycerophospholipids 1 0.96 0.9 
787.6085 + -2.266 4.73 C44H86NO8P PC(36:1) L2 Lipids: Glycerophospholipids 1 1.29 1.09 
807.5776 + -1.793 4.57 C46H82NO8P PC(38:5) L2 Lipids: Glycerophospholipids 1 1.38 1.27 
809.5936 + -1.318 4.58 C46H84NO8P PC(38:4) L2 Lipids: Glycerophospholipids 1 1.33 1.18 
883.536 + -2.269 3.95 C50H78NO10P PS(44:10) L2 Lipids: Glycerophospholipids 1 1.32 1.19 
 
 
 
